Indeed, TGFβ signaling has emerged as a central mediator of immune evasion and ICI resistance across a wide range of cancers, and many clinical trials are currently testing the combination of TGFβ and PD-1/PD-L1 immune checkpoint inhibition in patients with solid cancers [10,16,17,18,19,20]. The gene discussed is PDCD1; the disease is cancer.